実験的マウス結核症に対するｂｅｎｚｏｘａｚｉｎｏｒｉｆａｍｙｃｉｎ　ＫＲＭ‐１６４８のｉｎ　ｖｉｖｏ治療効果　（１）　　経気道感染モデルと尾静脈感染モデルを用いた短期治療効果の検討

• 土井 教生

  結核予防会結核研究所基礎研究部

書誌事項

タイトル別名

• Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis. (1) A Study on the Efficacy of Short Course Treatment with the Intratracheal and Intravenous Infection Models.
• (1) A Study on the Efficacy of Short Course Treatment with the Intratracheal and Intravenous Infection Models
• (1) 経気道感染モデルと尾静脈感染モデルを用いた短期治療効果の検討

抄録

Objectives: This study aims to compare in vivo activity of benzoxazinorifamycin KRM-1648 (KRM) with those of rifampicin (RFP) and rifabutin (RBT) against experimental murine tuberculosis.<BR>Study design: Mice were infected with Mycobacterium tuberculosis or M. bovis by the intratracheal (IT) or intravenous (IV) routes, and treated for 10 days with various doses of each drug starting from the 8th or 11th day after the TB-infection.<BR>Results: (A) A rapid test for in vivo evaluation of three rifamycins was conducted by examining the survival days of treated mice infected with 10⁶ cfu of M. bovis Ravenel. Mice treated with KRM exhibited 2.1-3.7 times longer survival times, in comparison with those treated with RFP or RBT. (B) In the IT-model of M. bovis Ravenel infection, three rifamycin derivatives gave “distinctive dose-response curves” in the correlation of dose sizes with the mean survival times or “log₁₀ CFU/lungs reductions”. (C) In M. tuberculosis Kurono infection models, the ranking of the anti-TB activity of the three rifamycins in each organ was as follows: IT-and IV-lungs: KRM>RFP=RBT, IV-spleen: KRM≈≈RBT>RFP, IV-liver: KRM≈RBT>RFP. (D) Based on the results of“log₁₀CFU reductions”in different organs in M. tuberculosis Kurono infection models, “characteristic in vivo activity patterns of each rifamycin” were obtained. (E) The therapeutic efficacy of KRM in lungs was greater than in spleen and liver with any dose. In contrast, RBT exhibited more remarkable in vivo activity in the spleen and liver than in lungs.<BR>Conclusion: The prominent in vivo activity of KRM may allow small dose for effective therapy;1/3 dose or less in comparison with those of RFP or RBT, or intermittent therapy of tuberculosis.

収録刊行物

• 結核

  結核 73 (2), 53-64, 1998

  一般社団法人 日本結核病学会

キーワード

• 経気道感染
• 結核菌
• マウス
• KRM-1648
• リファンピシン
• リファブチン

詳細情報

• CRID: 1390282679976363776
• NII論文ID: 10008113284
• NII書誌ID: AN00073442
• DOI: 10.11400/kekkaku1923.73.53
• ISSN: 18842410
• ISSN: 00229776
• PubMed: 9545697
• Web Site: https://search.jamas.or.jp/link/ui/1998136880
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可